[{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","amount":"$20.2 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Sinapultide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Windtree Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Lyophilized Powder","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"4","companyTruncated":"Windtree T.."}]

Find Clinical Drug Pipeline Developments & Deals for Sinapultide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioProcess International
                          Not Confirmed
                          BioProcess International
                          Not Confirmed

                          Details : Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinic...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 22, 2020

                          Lead Product(s) : Sinapultide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Ladenburg Thalmann & Co

                          Deal Size : $20.2 million

                          Deal Type : Public Offering

                          blank